FOOD – DiscussionPreviously thought about starting this thread based on population increase, scarcity and listening to Arch1 and HendrixNuzzles.
So here it is. Share your best ideas, news, equities and thoughts. Best2All ~ Ben
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
@Ethical_Corp Pastures new for big data: see our new magazine focused on the future of food #agritech #climatesmartagriculture
https://twitter.com/tslavinm/status/968042130118758405
#FutureFarming: Pastures new for #BIGdata
http://www.ethicalcorp.com/future-farming-pastures-new-big-data#.WpPGXsaJkIc.twitter
This article is part of our in-depth briefing on Future of Farming. See also:
From vertical farms to new proteins: innovating to feed the planet
http://www.ethicalcorp.com/vertical-farms-new-proteins-innovating-feed-planet
A sea change in the way we farm fish
http://www.ethicalcorp.com/sea-change-way-we-farm-fish
Can agri-tech sow a green revolution for India’s poorest farmers?
http://www.ethicalcorp.com/can-agri-tech-sow-green-revolution-indias-poorest-farmers
Applying AI to the humble potato
http://www.ethicalcorp.com/applying-ai-humble-potato
#Eat’em UP!
$CLXT – Calyxt Expands Total Acreage with Farmers for High-Oleic
Soybean Product
Minneapolis-St. Paul, Minn., March 1st, 2018 – Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced that the Company has expanded its total acreage with farmers across the United States for its high-oleic / no trans-fat soybean variety.
Highlights of Calyxt’s progress in preparing the high-oleic soybean launch include:
Calyxt has contracted over 10,000 acres with 50 farmers in the Midwest.
Overall, these growers collectively farm over 100,000 acres, half of which are expected to produce soybeans. Twenty percent of the soybeans that are anticipated to be planted consist of Calyxt’s high-oleic variety.
Calyxt’s recent partnership with Farmer’s Business Network, Inc. (FBN) added to the distribution and grower base of Calyxt’s identity-preserved high-oleic soybeans across the upper Midwest region, including South Dakota and Minnesota.
“The vast expansion of Calyxt’s high-oleic soybean variety, along with our strong grower retention year-over-year, signifies important advancements in our product offering as we prepare for the commercial launch of the soybeans later this year,” said Federico Tripodi, Calyxt CEO. “Calyxt is at the forefront of history when it comes to bringing to market crops with healthier characteristics and improved traceability that consumers want and need, and continuing to cultivate a dedicated, high-quality grower base in the upper Midwest region is key to our success.”
The high-oleic / low-saturated fat oil from this new variety of soybeans is designed to eliminate the need for hydrogenation, a process that improves heat stability and shelf life of conventional soybean oil. The process of hydrogenation contributes to the production of trans-fatty acids, which, when consumed, raises low-density lipoprotein, or LDL, and cholesterol levels, as well as contributes to cardiovascular diseases. The FDA has declared trans fats not generally recognized as safe (GRAS), and human food must no longer contain partially hydrogenated oils by June 18, 2018.
In mid-2015, Calyxt received a letter from the USDA confirming that the Company’s high-oleic soybean variety is non-regulated, as the product contains no foreign DNA.
About Calyxt
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).
For further information please visit our website: http://www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis Group.
For further information, please contact:
For Calyxt
Media contacts
Jennifer Moore, VP Communications
Phone: 917-580-1088
email: media@calyxt.com
Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
212.896.1241 / 212.896.1206
email: ckasunich@kcsa.com / nopich@kcsa.com
Investor Relations contact
Simon Harnest, VP Corporate Strategy and Finance
Phone: 646-385-9008
email: simon.harnest@calyxt.com
Calyxt Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995….
Despite Downturn, R&D Money Is Flowing Into Agriculture
https://www.agriculture.com/technology/crop-management/despite-downturn-r-and-d-money-is-flowing-into-agriculture
HT TY https://twitter.com/DrSManian/status/970452792958582785
$CLTX – Calyxt to Hold Fourth Quarter and Full-Year 2017 Investor Conference Call on Wednesday, March 14,
at 8 a.m. EDT – 7 a.m. CDT
Minneapolis-St. Paul, Minn., March 5, 2018 – Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced the company will hold a conference call for investors on Wednesday, March 14, 2018 at 8 a.m. EDT – 7 a.m. CDT. The call will include the company’s fourth quarter 2017 and year-end financial results.
The live dial-in information for the conference call is:
US & Canada only: 877-407-9747
International: 412-902-0044
In addition, a replay of the call will be available for 6 months following the conference by calling 877-660-6853 (Toll Free US & Canada); 201-612-7415 (Toll Free International). The archived webcast of this event may be accessed through the Calyxt website.
About Calyxt
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).
For further information please visit our website: http://www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis Group.
For further information, please contact: http://www.calyxt.com/
(Reuters) – Campbell Soup Co (N:$CPB) faces challenges but with its shares the cheapest they have been in years, the stock may be a bargain, Barron’s said in an article on Sunday.
Campbell faces a grocery war. Walmart Inc (N:WMT), Amazon.com Inc (O:AMZN), dollar stores like Dollar General Corp (N:DG) and drugstores like CVS Health Corp (N:CVS) are vying to take share from traditional grocers, according to the article.
A recent squabble with Walmart over soup promotions cut into Campbell’s sales, but Barron’s said the grocery war was also a sales opportunity since Campbell plans to expand distribution through dollar stores and drugstores.
Campbell is expected to grow revenue by a fraction of 1 percent in its fiscal year through July, while increasing earnings per share by 2 percent, Barron’s said.
With shares trading below $42 earlier this month, their lowest since 2014, Barron’s noted, “The discount on shares may be too large to ignore.” Campbell shares closed at $43.61 on Friday. https://www.investing.com/news/stock-market-news/campbell-soup-shares-could-be-a-bargain-after-decline-barrons-1335851
Calyxt Filed Complaint in Delaware Chancery Court Against Bayer CropScience, LP
Minneapolis-St. Paul, Minn., March 12, 2018 – Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced that it has filed a complaint in Delaware Chancery Court against Bayer CropScience, LP (“Bayer”).
In December 2013, Calyxt entered into a Research and Commercial License Agreement with Bayer pursuant to which it granted Bayer a license to certain patents for the research and commercialization of products developed with TALEN® technology. Calyxt believes that Bayer has breached the License Agreement by filing patent applications in violation of the License Agreement’s provisions and by failing to make a payment due under the License Agreement. Calyxt previously gave notice to Bayer of termination of the License Agreement, and today filed a complaint in Delaware Chancery Court requesting a declaration that the License Agreement has terminated for material breach and an order of specific performance requiring Bayer to comply with its post-termination obligations.
About Calyxt
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. Calyxt is pioneering a paradigm shift to deliver healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and crop traits that benefit the environment and reduce pesticide applications, such as disease tolerance, for farmers. Calyxt develops non-transgenic crops leveraging processes that occur in nature by combining its leading gene-editing technology and technical expertise with its innovative commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market (ticker: CLXT).
For further information please visit our website: http://www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by Cellectis.
$CLXT – Calyxt Reports Financial Results for Fourth Quarter
and Full-Year 2017
http://www.calyxt.com/calyxt-reports-financial-results-for-fourth-quarter-and-full-year-2017/
As of March 13th, successfully contracted over 11,500 high-oleic / no trans-fat soybean acres with over 60 growers.
Partnership with Farmer’s Business Network, Inc. (FBN) to expand distribution and grower base of identity-preserved high oleic soybeans in the upper Midwest; Launched FBN seed distribution and 2018 High Oleic Premium Grower Program
Around a dozen small to large food company customers engaged across food services and food ingredient applications
Advanced two product candidates from ‘discovery’ to ‘phase 1′ development
New concept-to-fork facility in Roseville, Minn., on track for completion in Spring 2018
Minneapolis-St. Paul, Minn., March 13, 2018 – Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced its results for the three-month period ended December 31, 2017 and for the year ended December 31, 2017.
Investor Call Details
Calyxt will host an investor call on March 14, 2018 at 8:00 am Eastern Time to discuss its financial results and provide a general business update.
The live dial-in information for the conference call is:
US & Canada only: 877-407-9747
International: 412-902-0044
In addition, a replay of the call will be available for 6 months following the conference by calling 877-660-6853 (Toll Free US & Canada); 201-612-7415 (Toll Free International). The archived webcast of this event may be accessed through the Calyxt website.
Webcast URL (Archived for 6 months): http://calyxt.equisolvewebcast.com/q4-2017
“At Calyxt, we are pioneering a business model as a specialty food ingredient company, based on our proprietary, industry-leading gene editing technology platform, called TALEN®. We have made tremendous progress in the commercial preparation of our High Oleic Soybean product by contracting over 11,500 acres with over 60 farmers as of March 13th. This is just our first product and we are thrilled by the pace of development and possibilities that gene editing brings to the agricultural space as a whole.” Federico Tripodi, CEO Calyxt.
Corporate highlights
Planting Update – On Track for the Commercialization of High Oleic Soybeans
As of March 13th, Calyxt has contracted over 11,500 acres with 60 farmers in the Upper Midwest. Overall, these growers collectively farm over 125,000 acres, half of which are expected to produce soybeans. More than a quarter of the soybeans that are anticipated to be planted by these farmers consist of Calyxt’s high-oleic variety.
Calyxt’s recent partnership with Farmer’s Business Network, Inc. (FBN) added to the distribution and grower base of Calyxt’s identity-preserved high-oleic soybeans across the upper Midwest region, including South Dakota and Minnesota.
In December 2017, Calyxt launched the seed distribution and 2018 High Oleic Premium Grower Program with the Farmer Business Network. With access to a growing network of progressive farmers covering the entire U.S., we are building out our grower program with FBN.
On the food customer side, around 12 small to large food company customers are currently engaged across food services and food ingredient applications to test Calyxt’s high oleic soybean oil.
Alfalfa Product Candidate Designated as Non-Regulated by USDA and two product candidates advanced from ‘discovery’ to ‘phase 1′ development
In October, Calyxt and S&W Seeds announced that Calyxt’s first alfalfa product candidate has been designated by the USDA as a non-regulated article under the USDA APHIS’s “Am I Regulated?” Process.
This improved quality alfalfa developed using Calyxt’s proprietary gene editing technology TALEN® is Calyxt sixth product candidate to be confirmed as a non-regulated article by the USDA together with Calyxt’s high oleic soybean, high oleic / low linolenic soybean, powdery mildew resistant wheat, cold storable potato and reduced browning potato.
Calyxt now has nine product candidates in Phase 1 development or higher across soybean, wheat, canola, potato and alfalfa crops. The two products most recently entering Phase 1 are herbicide-tolerant wheat, our third wheat product candidate, and improved oil composition canola, our first canola product candidate, which entered Phase 1 during the third quarter of 2017. We believe that canola and wheat represent major growth opportunities for Calyxt.
New concept-to-fork facility in Roseville, Minn., on track for completion in Spring 2018
Calyxt’s new 11-acre concept-to-fork facility will house Calyxt’s nearly 40,000-square-foot headquarters, state-of-the-art research labs and a test kitchen. The new facility is being constructed adjacent to Calyxt’s recently completed 11,000+square-foot greenhouses and existing outdoor demonstration plots.
Financial Highlights
Cash and cash equivalents were $56.7 million at December 31, 2017. The highlight of 2017 was the successful initial public offering (IPO) in July, which provided $58 million of net proceeds after underwriter discounts and fees. Cellectis remains our majority shareholder with 79.7% of our common stock as of December 31, 2017. In September 2017, we completed a sale-leaseback transaction with respect to our Roseville, Minnesota headquarters and lab facilities, in which we received approximately $7 million for the sale of the property and entered into a lease agreement with an initial twenty-year term. We intend to continue to judiciously manage the use of cash and expect to have sufficient cash to fund the business through the mid-2019.
For the fourth quarter and full year of 2017, we had a net loss of $6.8 million and $26.0 million respectively. The net loss includes non-cash stock option expense related to grants from 2014 to 2017 for the fourth quarter and full year of $2.1 million and $12.1 million respectively. Our operating cash spend for the 12 months ending December 31, 2017 was $12.8 million or approximately $1.1 million per month.
Looking forward towards 2018, we anticipate that our operating cash spend will increase as we continue to expand our R&D team to advance key products in the portfolio and build out or commercial capabilities. For the first quarter of 2018, we project a cash burn rate in the range of $6.0 to $7.0 million. This increased cash spend reflects spending in the first half of 2018 on high oleic soybean seed production to support our Spring product launch, a continued expansion of our R&D team to advance key products in the portfolio and the build-out of our commercial capabilities… #GrowIt! 🙂 #Best2ALL!
$RKDA – Arcadia Biosciences Achieves Key Resistant Starch Wheat Technology Milestones, Prepares for Commercial Launch
8:00 am ET March 14, 2018 (BusinessWire) Print
Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company, today announced that it has achieved two key technology milestones in its High Fiber Resistant Starch (RS) Wheat program. First, through advanced screening and traditional breeding techniques, the company has developed non-transgenic (non-GM) wheat varieties that contain up to 94 percent amylose, the highest levels available. Increased levels of amylose correspond to high levels of resistant starch, which has been proven to deliver significant health benefits. Second, these same wheat varieties deliver levels of total dietary fiber high enough to meet the threshold required by the US Food and Drug Administration for a “Good Source” of fiber or “High in Fiber” designation on consumer packaging.
“These milestones are key achievements in the commercial launch plan for our non-GM wheat ingredients portfolio, delivering health benefits to consumers and distinct market differentiators to consumer packaged goods companies,” said Raj Ketkar, president and CEO of Arcadia Biosciences. “Arcadia’s new wheat varieties will allow people to enjoy the foods they love with the health benefits of resistant starch and dietary fiber, while satisfying consumer demand for clean-label, natural foods.”
Arcadia is working with a select number of consumer packaged goods companies on new, healthier formulations of existing products using both enriched and whole wheat RS Wheat flour. The company is preparing for an increase in acres planted during the upcoming US wheat growing season.
Resistant starch has many benefits compared to other types of starch, particularly in the management of gastrointestinal health and obesity-related health conditions, such as cardiovascular disease and type 2 diabetes. It contains higher amounts of amylose, a carbohydrate molecule that is less vulnerable to digestion. Because it is digested more slowly, resistant starch has a lower glycemic index, meaning it does not cause a rapid increase in blood glucose levels. Resistant starch also acts as a nondigestible prebiotic that promotes the growth of “good bacteria” (probiotics) that improve gut health.
Some of the additional reported health benefits of resistant starch include:
– Increased absorption of calcium and other key minerals
– Improved weight loss through increased feeling of satiety
– Increased insulin sensitivity – helpful for cardiovascular disease, type 2 diabetes, metabolic syndrome, obesity and Alzheimer’s disease
– Increased production of butyrate – an anti-inflammatory which may help burn body fat and recently consumed fat.
In addition to the benefits of resistant starch, Arcadia’s RS Wheat varieties produce refined flour and whole grain flour that is naturally high in fiber. Many products marketed as “high fiber” contain fiber additives, such as inulin, cellulose and psyllium husk. Arcadia’s RS Wheat has intrinsically high levels of fiber and can enable food companies to reduce the use of added fiber sources in their formulations to simplify their ingredient labels.
Wheat flour is a major part of people’s diets on a global level. In 2015, the global wheat flour market was valued at $200 billion and is estimated to reach a value of $270 billion by 2022. On average, one quarter, or 500 calories, of Americans’ daily caloric intake comes from wheat. Arcadia’s RS Wheat varieties have the opportunity to provide additional, proven health benefits for consumers who want to continue to enjoy the wheat-based foods they love.
About Arcadia Biosciences, Inc.
Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers, enhance human health and improve the environmental sustainability of agriculture. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. Arcadia’s agronomic performance traits are aimed at making agricultural production more economically efficient and environmentally sound. For more information, visit http://www.arcadiabio.com.
Note Regarding Forward-Looking Statements… #BEST2ALL!
$RKDA – This has unleaded some absolutely amazing buying today.
$YTEN – Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.
https://www.yield10bio.com/
#Best2ALL!
$YTEN – The USDA Just Gave the Green Light to CRISPR’d Food
https://gizmodo.com/the-usda-just-gave-the-green-light-to-crisprd-food-1824213151?
Website: https://www.yield10bio.com/
Regarding CRISPR technology, Has anyone investigated the NEXGEN teaser about a $200 biotech stock that could reach 1 million in the next 30 years? I have found a few but they don’t seem to match the teaser. The closest one I found was Vertex Pharmaceuticals
Is Gene Editing the Future of Farming https://www.wsj.com/video/is-gene-editing-the-future-of-farming/180223BD-1B01-4972-8B3C-E6CDBCE17ED7.html …? $SGMO $CLXT $CLLS #geneediting
Thx Sheff Long $CLXT #DYODD #NIAIA
#$YTEN fp http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20180424:nGNX8RtvLy
WOBURN, Mass., April 24, 2018 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (NASDAQ:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced plans for its 2018 Field Test Program. The main focus of the 2018 Program will be on the novel yield trait gene C3003 in Camelina, canola and soybean. The Company recently obtained permits allowing these tests to be conducted at sites in Canada. Yield10 plans to conduct an additional study in the U.S. of Camelina lines that have been genome edited to inactivate the C3008 gene as part of a new multi-trait approach to increase seed oil content and to potentially improve oil stability. Yield10 expects to begin planting during the second quarter with timing dependent upon suitable weather and soil conditions, and to report results of the field tests beginning in the fourth quarter of 2018.
A summary of Yield10’s 2018 Field Test Program:
Camelina/C3003: Yield10 will test Gen 2.0 and 2.1 versions of C3003 in Camelina from seed produced during its 2017 field tests.
Canola/C3003: Yield10 will test Gen 1.0 C3003 from seed produced in its 2017 field tests, and for the first time will conduct a field test of Gen 2.0 C3003 in canola using recently harvested greenhouse grown seed.
Soybean/C3003: Yield10 will conduct small-scale field work for the first time for Gen 1.0 and Gen 2.0 C3003 in soybean using recently harvested greenhouse grown seed.
Camelina/C3008: Yield10 will conduct field tests with genome-edited C3008 lines for which the Company obtained non-regulated status from USDA-APHIS in 2017.
In the field tests of C3003 in Camelina and canola, Yield10 will monitor key agronomic and growth parameters of the plants throughout the growth period, and will collect seed yield data including seed weight and oil content after harvest. All measurements of C3003 lines will be compared to control plants. The objective of the Camelina and canola tests is to evaluate multiple constructs of C3003 to enable optimization of the trait to increase seed yield in major oilseed crops.
$YTEN fp + at $1.82 this a.m.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-release-details/yield10-addresses-application-metabolic-engineering-increase
Yield10 Addresses Application of Metabolic Engineering to Increase Crop Yield in Paper Published in Plant Science
Chief Science Officer Kristi Snell also confirmed as a keynote speaker at upcoming plant meeting
WOBURN, Mass., April 26, 2018 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (NASDAQ:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today highlighted upcoming events in the form of a scientific research paper published in Plant Science, a leading peer-reviewed scientific journal, as well an upcoming presentation at a plant conference in late April. Both opportunities are a result of Yield10’s innovative approach to engineering gene traits designed to increase crop yield, and the Company’s status as a leading voice and thought leader in the agricultural innovation sector.
The paper, entitled “Metabolic Engineering to Increase Crop Yield: From Concept to Execution,” is authored by Yield10 employees and leadership including Frank A. Skraly, Madana M.R. Ambavaram, Oliver Peoples, and Kristi D. Snell, and is part of a special issue of Plant Science, an international journal of experimental plant biology. It discusses how trait discovery programs can benefit from smart approaches that incorporate predictive models to identify novel gene targets to increase yields in key crops. The paper references Yield10’s own trait discovery program, and examines various external factors that impact the cost and timeline to reach commercialization.
On April 28, Chief Science Officer Kristi Snell, Ph.D., will present as one of the keynote speakers at the Northeast Section of The American Association of Plant Biologists (ASPB) 2018 meeting, held at the University of Massachusetts (UMASS), Amherst. At the meeting, she will discuss how step-change increases in crop yield will require innovators to build better plants. Snell will discuss the Company’s multifaceted approach to discovering gene targets that boost plant productivity, including the use of in silico analyses of plant metabolism and gene networks. Yield10 relies on targeted design strategies for plant metabolic engineering, as opposed to the mass screening and trial-and-error approaches that have stagnated the development in this sector within the crop industry for the past 20 years.
“We are pleased to participate in these opportunities to demonstrate and discuss how we apply our unique metabolic engineering skill sets to increase crop yield,” said Kristi Snell, Chief Science Officer at Yield10 Bioscience, Inc. “We believe our trait discovery programs, which incorporate targeted rational design strategies with genome editing tools, are a clear differentiator from existing industry approaches, and will continue to serve as the basis for our research and scientific collaborations with leading universities and agtech companies.”
AboutYield10 Bioscience
Yield10 Bioscience, Inc. is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. Yield10 is leveraging its technology platforms and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and rice. Yield10 is headquartered in Woburn, MA and has an Oilseeds center of excellence in Saskatoon, Canada.
For more information about the company, please visit http://www.yield10bio.com.
(YTEN-G)
Safe Harbor for Forward-Looking Statements … #Best2ALL!
$YTEN fp > Yield10 Addresses Application of Metabolic Engineering to Increase Crop Yield in Paper Published in Plant Science
Chief Science Officer Kristi Snell also confirmed as a keynote speaker at upcoming plant meeting April 28, 2018 #ThankYOU Antonio Costa https://finance.yahoo.com/news/yield10-addresses-application-metabolic-engineering-123000947.html
https://twitter.com/ACInvestorBlog/status/989948010233778176
$YTEN, $CLXT fp & #CRISPR stocks… Eatin’ CRISPR food in 5 years maybe
https://www.ozy.com/fast-forward/you-could-be-eating-crispr-food-in-five-years/85431 ht thx https://twitter.com/Genomics_2018/status/979715650540023809
Vertical farm in Singapore, produces 100 Kg of vegetables per tower. System produces 10 times more food per hectare than conventional farm, uses very little energy or water, is relatively maintenance-free and produces green vegetables in 28 days or less https://twitter.com/AgBioWorld/status/1005994845100498944
$RKDA > Arcadia Biosciences and Shriram Bioseed Reach Milestone in Developing Extended Shelf Life Tomatoes http://ir.arcadiabio.com/news-releases/news-release-details/arcadia-biosciences-and-shriram-bioseed-reach-milestone
$CLTX long > Calyxt and S&W Seed Company Announce Milestone in Alfalfa Seed Development Program
MINNEAPOLIS & ST. PAUL, Minn. & SACRAMENTO, Calif – July 19, 2018 – Calyxt, Inc. (Nasdaq: CLXT), a consumer-centric, food- and agriculture-focused company, and S&W Seed Company (Nasdaq: SANW), a global leader in the alfalfa seed industry, today announced the successful transfer of their proprietary alfalfa seed and plants from the research and development facility at Calyxt to S&W for field evaluation and testing. This marks a significant milestone in the collaboration between the two companies.
In 2015, Calyxt and S&W Seed Company embarked on a collaboration to research, develop, produce and commercialize alfalfa seed products involving Calyxt’s proprietary gene editing technology, TALEN®, and S&W’s industry-leading alfalfa seed genetics. The collaboration between Calyxt and S&W is focused on providing enhanced traits in alfalfa that can drive improved productivity, while decreasing input costs to meet the growing global demand for improved quality alfalfa seeds.
The affirmation of the strategy to utilize Calyxt’s proprietary gene editing technology as a way to develop non-regulated varieties occurred in October 2017 when the first alfalfa targeted mutations had been designated as a non-regulated article under the “Am I Regulated?” process by the Biotechnology Regulatory Services of the Animal and Plant Health Inspection Service (APHIS), an agency of the U.S. Department of Agriculture (USDA). The improved quality alfalfa product was the first-ever alfalfa product to receive this non-regulated distinction from the USDA.
S&W will now conduct open field trials throughout the United States to progress the development and characterization of new varieties with this enhanced digestibility trait.
Mark Wong, CEO of S&W Seed Company, commented, “Unique trait technology in alfalfa seed varieties that are non-regulated, and are available to be grown by farmers in regions that currently prohibit GMO trait technology, is considered by many to be the holy grail within our industry. Today’s announcement of the successful molecular trait development work by Calyxt and commensurate transfer of the plants to S&W for field trials is an important milestone in advancing that outcome.”
“Advancing this improved quality alfalfa crop to field trials marks yet another major step in our mission to develop specialty food ingredients that have agriculturally advantageous traits for farmers. In addition, it proves Calyxt’s gene editing platform and product development capabilities in multiple crops,” said Federico Tripodi, CEO of Calyxt. “We look forward to continuing to work closely with our partner S&W Seed Company as we push forward toward commercialization and bringing our first alfalfa product to market in the near future.” ,,, Best